Antitumor vaccination with synthetic mRNA: Strategies for in vitro and in vivo preclinical studies

Methods in Molecular Biology

Volumn 969, Issue , 2013, Pages 235-246

  Diken, Mustafa ^a   Kreiter, Sebastian ^a   Selmi, Abderraouf ^a,b   Türeci, Özlem ^c   Sahin, Ugur ^a,b,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Ganymed Pharmaceuticals   (Germany)

^d BIONTECH AG   (Germany)

Author keywords

Cancer immunotherapy; Dendritic cell; Lymph node; MRNA vaccination

Indexed keywords

CANCER VACCINE; MESSENGER RNA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CELL COUNT; DENDRITIC CELL; DRUG BIOAVAILABILITY; ELECTROPORATION; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; AUTOTRANSPLANTATION; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; REVIEW; SYNTHESIS; TRANSPLANTATION; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; NEOPLASMS; RNA, MESSENGER; TRANSFECTION; TRANSPLANTATION, AUTOLOGOUS; VACCINATION;

MLCS; MLOWN;

EID: 84878642106     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-260-5_15     Document Type: Article

References (25)

1. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene-transfer into mouse muscle in vivo. Science 247:1465-1468
2. Conry RM, Lobuglio AF, Wright M, Sumerel L, Pike MJ, Feng JN, Benjamin R, Lu D, Curiel DT (1995) Characterization of a messenger-RNA polynucleotide vaccine vector. Cancer Res 55:1397-1400
3. Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of speci fic cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1-7
4. Kariko K, Buckstein M, Ni HP, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modi fication and the evolutionary origin of RNA. Immunity 23:165-175
5. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK (2002) Induction of tumor-speci fic cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235:540-549
6. Granstein RD, Ding WH, Ozawa H (2000) Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 114:632-636
7. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
8. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN (2001) Highly ef ficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49-56
9. Ponsaerts P, Van den Bosch G, Cools N, Van Driessche A, Nijs G, Lenjou M, Lardon F, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF (2002) Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol 169:1669-1675
10. Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P (2006) Intralymphatic dendritic cell vaccination induces tumor antigen-speci fic, skin-homing T lymphocytes. Clin Cancer Res 12:5801-5808
11. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964-971
12. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells transfected with prostate-speci fic antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109:409-417
13. Kreiter S, Diken M, Selmi A, Tureci O, Sahin U (2011) Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23:399-406
14. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee HG, Pascolo S (2004) Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 61:2418-2424
15. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O, Sahin U (2006) Modi fication of antigen-encoding RNA increases stability, translational ef ficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108:4009-4017
16. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE (2001) Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3 ¢ -O-methyl)GpppG and 7-methyl(3 ¢ -deoxy)GpppG. RNA 7:1486-1495
17. Pasquinelli AE, Dahlberg JE, Lund E (1995) Reverse 5 ¢ caps in RNAs made in vitro by phage RNA polymerases. RNA 1:957-967
18. Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, Darzynkiewicz E, Huber C, Tureci O, Sahin U (2010) Phosphorothioate cap analogs increase stability and translational ef ficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 17:961-971
19. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O, Sahin U (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70:9031-9040
20. Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Husemann Y, Koslowski M, Huber C, Tureci O, Sahin U (2011) FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res 71:6132-6142
21. Weide B, Pascolo S, Scheel B, Derhovanessian E, P fl ugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C (2009) Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32:498-507
22. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S (2008) Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31:180-188
23. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical bene fit in vaccinated patients. Mol Ther 19:990-999
24. Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Tureci O, Sahin U (2011) Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 18:702-708
25. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77-92